Arax Capital Partners
VC Fund
Vienna, Austria
ARAX Capital Partners is an Austrian bio-tech and high-tech early stage investor with an exclusive focus on Austrian ventures. Companies need to be young, innovative (if possible with patentable technology) and must have already secured pre-seed funding to qualify for an investment
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
- Fund size:
- $88M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Arax Capital Partners invests in
BiotechnologySoftwareHealth CareInformation TechnologyRFID
Stages Arax Capital Partners invests in
SeedVenture - Series UnknownSeries AFunding Round
Countries Arax Capital Partners invests in
AustriaUnited States
Round sizes
Seed $687k–$1.1MVenture - Series Unknown $600k–$10M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $687k–$1.1M
- Venture - Series Unknown
- $600k–$10M
Investment Focus
Industry
- Biotechnology 3 (27%)
- Software 2 (18%)
- Health Care 2 (18%)
- Information Technology 2 (18%)
- RFID 1 (9%)
Stage
- Seed 4 (36%)
- Venture - Series Unknown 4 (36%)
- Series A 1 (9%)
- Funding Round 1 (9%)
Country
- Austria 8 (73%)
- United States 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christian Tiringer
Partner and Founder
|
Partner and Founder | Total investments: 0 | Find email | |
|
Daniel Cesky
Partner
|
Partner | Total investments: 0 | Find email | |
|
Lena Skaper
Office Management
|
Office Management | Total investments: 0 | Find email | |
|
Michael Stranz
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Rumman Syed
Managing Director - Smart Capital GmbH
|
Managing Director - Smart Capital GmbH | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Greenpass is an all-in-one SaaS for climate-resilient urban planning & architecture platform that enables livable cities. | Seed / Sep 24, 2024 | ||
| Calyxha is developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases. | $1.1M / Seed / Feb 28, 2020 | ||
| EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against Shigella as well as against ETEC bacteria. Both bacterial strains cause various types of diarrheal diseases, and all attempts at development of vaccines have so far only aimed to protect against one ofthe two bacterial strains. The team led by Managing Director Gábor Somogyi has succeeded for the first time in producing a combined swallow vaccine that simultaneously protects against both bacterial strains. | $2.8M / Series A / Jul 01, 2019 | ||
| The MoonVision GmbH is a young company located in the heart of Vienna, Austria, focussed on transferring expert know-how to AI using visual information. The company was founded in August 2017, and was awarded with the title “Startup of the year” in 2017. In 2018 it was nominated for the “Go Silicon Valley Program” by WKO and won over partners likeAudi, A1, Sacher and Miba. MoonVision detects item type and amounts on a visual basis using proprietary computer vision algorithms and triggers events, like the optimization of machines, payment processes or data generation. | $686.9K / Seed / Jan 31, 2019 | ||
| crystalsol develops an entirely new type of flexible photovoltaic technology. The patented technology combines the advantages of high efficiency single-crystalline materials and low cost roll-to-roll production.The technology is based on decades of research for the Russian military and Philips semiconductor know-how from the 1960s. The coreinnovation is the light absorbing layer made of a patented new crystalline semiconductor powder.The light absorbing active layer of the film is made of crystalline semiconductor particles with a typical diameter of 40 μm arranged as a single layer fixed by a polymer film.The semiconductor particles contain the abundant and low-cost elements copper, zinc, tin, sulphur, and selenium (CZTS). Every semiconductor particle is coated with an extremely thin buffer layer to create the p/n junction. Before the crystalline powder enters the module production it is already a finished working solar cell. The module production process is based on roll-to-roll technology ensuring high throughput and yield similar to the printing industry.Consequently the required investment in crystalsol’s manufacturing equipment is significantly below current capital requirements for photovoltaic plants. Main reason is the elimination of vacuum technology for the active layer and the low process temperatures.Due to the characteristics of crystalsol’s technology upscaling issues – common for thin film technologies – are minimized. As every semiconductor particle is a tiny photovoltaic cell it does not make a difference how large the finished film is. This is an advantage compared to all thin film technologies where all upscaling to larger areas requires costly and time consuming development. | $599.8K / Venture - Series Unknown / Dec 31, 2016 | ||
| AIRBORNE ROBOTICS drones are delivered worldwide as a complete package, including all the relevant software as well as flight training. The moment one of their customers receives his new AIR6 or AIR8, he can immediately get down to business. The carrier system of an AIR6/8 can accommodate a variety of cameras: Film and photo, thermal imagingcameras, infrared, and diverse measuring sensors for environmental analysis. The system can therefore be adapted to the widest array of applications. Designed as an open platform for developers, specialists from many different fields can program an AIR flying robot for their own purposes and flight jobs, since the interfaces and software are freely accessible. | Venture - Series Unknown / Sep 16, 2016 | ||
| Identec Solutions provides its customers with RFID based solutions to help better manage their processes and track whatever their particular situation requires. They focus on a number of sectors, including automotive, transportation, logistics, oil, gas, offshore, mining, marine and ports.Founded in 1999, IDENTEC SOLUTIONS immediately set theindustry standard in the RFID industry with the introduction of its Intelligent Long Range® (ILR®) technology, a breakthrough in the world of low-power, long-range wireless communication.In 2006, IDENTEC SOLUTIONS acquired a premier industrial RFID supplier to the automotive industry. Today, one of every three vehicles is manufactured with wireless technology pioneered by IDENTEC SOLUTIONS. The acquisition of WTEK in 2007, a Norway based personnel safety solution provider to the Oil, Gas, Tunnel and Mining industries, led to the expansion of IDENTEC SOLUTIONS’ award-winning RFID technology portfolio, which enabled the company to become an established provider of complete solutions to this burgeoning market. The 2010 acquisition of Sattel from DP World fuelled IDENTEC SOLUTIONS’ ongoing commitment to offering complete, high-value applications and technologies for the Marine and Intermodal industry. | $610.5K / Venture - Series Unknown / Jun 30, 2016 | ||
| AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions. | $10M / Venture - Series Unknown / Jun 28, 2016 | ||
| Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria.The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease whichis one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications.Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development. | Seed / Nov 02, 2015 | ||
| Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, andanalysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably. | $1.6M / Mar 25, 2010 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
112,472 investors
Enterprise Investors
88,017 investors
Software Investors
55,440 investors
Health Care Investors
47,147 investors
Hardware Investors
44,475 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
SaaS VC Funds
69,112 investors
Enterprise VC Funds
56,373 investors
FAQ
What does Arax Capital Partners invest in?
Arax Capital Partners invests primarily in Biotechnology, Software and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 11 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arax Capital Partners's check size?
Arax Capital Partners typically joins rounds of $687k–$1.1M at Seed and $600k–$10M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arax Capital Partners participates in.
How do I contact Arax Capital Partners?
Public channels for Arax Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Arax Capital Partners?
The team at Arax Capital Partners includes Christian Tiringer (Partner and Founder), Daniel Cesky (Partner) and Lena Skaper (Office Management). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
